Niemann–Pick disease, type C

Oragenics Issues Update to Shareholders

Retrieved on: 
Thursday, November 2, 2023
Biotechnology, FDA, Health, Other Health, Pharmaceutical, Other Science, Research, Managed Care, Infectious Diseases, General Health, Science, COVID-19, Clinical Trials, Medical Supplies, Niemann–Pick disease, type C, Oragene, Optimism, Acquisition, Common stock, Growth, Concussion, Internet, Administration, Series, Pharmaceutical industry, Security (finance), Odyssey

On October 5, 2023, we proudly announced that we had entered into an agreement to acquire Odyssey Health, Inc.’s lead assets.

Key Points: 
  • On October 5, 2023, we proudly announced that we had entered into an agreement to acquire Odyssey Health, Inc.’s lead assets.
  • The assets are related to Odyssey’s proprietary neurological drug therapies, including their proprietary formulation and nasal delivery system.
  • We understand concerns about potential dilution and its impact on shareholders.
  • Thank you for your continued support of Oragenics.

Cyclo Therapeutics Announces Early Exercise of Warrants by Board Members, Management and a Significant Shareholder Resulting in Cash Proceeds of $2.4 Million

Retrieved on: 
Monday, October 23, 2023
Biotechnology, Pharmaceutical, Health, Science, Good Company (company), CYTH, Exercise, NPC, Phase, Niemann–Pick disease, type C, Therapy, Patient, Security (finance), Management, Cyclo

The New Warrants will be exercisable for cash only and have a term of four years from the issuance date.

Key Points: 
  • The New Warrants will be exercisable for cash only and have a term of four years from the issuance date.
  • The Investors include Rafael Holdings, Inc., a significant shareholder of the Company, several directors of the Company, Company management, and their affiliates.
  • N. Scott Fine, CEO of Cyclo Therapeutics, commented, “We continue to navigate through difficult market conditions with the best interest of our shareholders in the near and long term as a priority.
  • The Offering was conducted pursuant to the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (“Securities Act”).

Oragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug Candidate

Retrieved on: 
Thursday, October 5, 2023
Biotechnology, General Health, Mental Health, Health, Pharmaceutical, OTCQB, Sport, NYSE, Concussion, Anxiety, Series, Inflammation, Brain, Trial of the century, Therapy, Animal, NPC, Safety, Memory, FDA, Science, Niemann–Pick disease, type C, Human, Oxidative stress, Pharmaceutical industry, Oragene, Odyssey

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) and Odyssey Health, Inc. (OTCQB: ODYY ) (“Odyssey”) announce the signing of a definitive agreement under which Oragenics will acquire Odyssey’s assets related to its proprietary neurological drug therapies and technologies.

Key Points: 
  • Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) and Odyssey Health, Inc. (OTCQB: ODYY ) (“Odyssey”) announce the signing of a definitive agreement under which Oragenics will acquire Odyssey’s assets related to its proprietary neurological drug therapies and technologies.
  • The asset purchase includes cash payments to Odyssey totaling $1.0 million and eight (8) million shares of Oragenics’ Series F Convertible Preferred Stock.
  • After closing this transaction, certain members of Odyssey management intend to join Oragenics and lead the continued development of Odyssey’s pipeline of neurological drug therapies and technologies.
  • “Our lead drug candidate for treating concussion has performed well in preclinical studies, generating promising efficacy and safety data in animal models.

Cyclo Therapeutics Announces Publication of Positive Data from Phase 2 Clinical Study of Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1

Retrieved on: 
Thursday, June 29, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Central nervous system, NPC1, CYTH, Brain, Cell, Lung, Trial of the century, Molecular genetics, Spleen, MD, Patient, Manuscript, HIV disease progression rates, Liver, NPC, Niemann–Pick disease, type C, Therapy, DSM-IV codes, Safety, Disease, Pharmaceutical industry

“The data seen to-date provide support for the capacity of Trappsol® Cyclo™ to alter the disease on a biochemical level, including in the central nervous system, and improve clinical signs and symptoms of NPC.

Key Points: 
  • “The data seen to-date provide support for the capacity of Trappsol® Cyclo™ to alter the disease on a biochemical level, including in the central nervous system, and improve clinical signs and symptoms of NPC.
  • In these Phase 2 data, all three doses of Trappsol® Cyclo™ were well-tolerated overall with efficacy across multiple clinical endpoints of intravenous (IV) administration of Trappsol® Cyclo™.
  • Cyclo Therapeutics continues to advance enrollment in its ongoing pivotal Phase 3 study, TransportNPC™ .
  • N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics, commented, “We first provided this investigational therapy to address symptoms of NPC back in 2009.

Cyclo Therapeutics Announces Abstract Accepted for Poster Presentation at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting

Retrieved on: 
Wednesday, January 4, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Natural history, Therapy, Annual general meeting, MD, Society, Science, CYTH, Trial of the century, Niemann–Pick disease, type C, Patient, SIMD, Doctor of Philosophy, NPC, Pharmaceutical industry

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced its abstract has been accepted for poster presentation at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting being held March 18 - 21, 2023, in Salt Lake City, Utah.

Key Points: 
  • Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced its abstract has been accepted for poster presentation at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting being held March 18 - 21, 2023, in Salt Lake City, Utah.
  • “We value the opportunity to participate in the upcoming SIMD Annual Meeting and further connect with all those dedicated to advancing science and clinical research to further elucidate the etiology and natural history of inherited metabolic disorders.
  • We look forward to further engaging with the community at this important meeting and bringing more awareness to our clinical study and the significant unmet need that persists,” added Dr. Kjems.
  • Details of the poster presentation are as follows:
    For more information about the event, please visit the conference website here .

Cyclo Therapeutics Announces Publication of Phase 1 Data for Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

Retrieved on: 
Tuesday, October 18, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Niemann–Pick disease, Niemann–Pick disease, type C, Science, Traffic barrier, Priority review, Protocol, Expanded access, Death, Journal, Half-life, Molecular genetics, Biomarker, Intravenous therapy, Lung, Plasma, Therapy, PPCS, Spleen, Serum, Company, Hearing loss, Cerebrospinal fluid, Hypersensitivity pneumonitis, C1, NPC1, Neurology, Manuscript, Central nervous system, Risk, Metabolism, CSF, Diagnosis, Security (finance), Cell, Filipin, NPC, Lists of diseases, U.S. Securities and Exchange Commission, CNS, Neurodegeneration, Week, CYTH, Form 10-K, Disease, Cholesterol, Patient, Nasdaq, Molecular Genetics and Metabolism, Learning, Society, Adult, Safety, Liver, Brain, Pharmaceutical industry, MD, EU

The data seen to-date provide support for the capacity of Trappsol Cyclo to stabilize disease progression with intravenous infusions in NPC.

Key Points: 
  • The data seen to-date provide support for the capacity of Trappsol Cyclo to stabilize disease progression with intravenous infusions in NPC.
  • In these Phase 1 data, Trappsol Cyclo cleared cholesterol from the liver and improved peripheral and central nervous system biomarkers of cholesterol homeostasis.
  • I am pleased with the progress weve made and look forward to learning more about the full potential of Trappsol Cyclo for the treatment of NPC.
  • Cyclo Therapeutics continues to advance enrollment in its ongoing pivotal Phase 3 study, TransportNPC evaluating Trappsol Cyclo for the treatment of NPC1.

Cyclo Therapeutics to Present at the World Orphan Drug Congress USA 2022

Retrieved on: 
Monday, July 11, 2022
General Health, Health, Genetics, Pharmaceutical, Clinical Trials, Protocol, CYTH, Drug development, U.S. Securities and Exchange Commission, Therapy, Disease, Form 10-K, Risk, Doctor of Philosophy, Investor, NPC, Company, Government, Niemann–Pick disease, type C, Congress, Nasdaq, Niemann–Pick disease, Patient, MD, Security (finance), Expanded access, Science, Pharmaceutical industry

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (Cyclo Therapeutics or the Company), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that Lise Kjems, MD, PhD, Chief Medical Officer of Cyclo Therapeutics will present at the World Orphan Drug Congress USA 2022 being held July 11-13, 2022 in Boston, MA.

Key Points: 
  • Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (Cyclo Therapeutics or the Company), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that Lise Kjems, MD, PhD, Chief Medical Officer of Cyclo Therapeutics will present at the World Orphan Drug Congress USA 2022 being held July 11-13, 2022 in Boston, MA.
  • The World Orphan Drug Congress brings together leading pharmaceutical and biotech companies, government and regulatory authorities, patient advocacy groups, payers, investors and solution providers.
  • The conference is a place to meet and brainstorm ways to advance orphan drug development and improve access to life-saving therapies.
  • Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease.

Global Allergic Conjunctivitis Market Report (2022 to 2027) - Players Include Ocular Therapeutix, Portola Pharmaceuticals and Alcon - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 31, 2022
Health, Other Health, Giant, GPC, Urbanization, AKC, Population, Allergic conjunctivitis, Incidence, Conjunction (grammar), Patient, OTC, Cetirizine, Transport, COVID-19, OA, Awareness, SAC, PAC, Adoption, VKC, Vernal keratoconjunctivitis, CAGR, Prevalence, Allergen, Niemann–Pick disease, type C, Health insurance, Pharmaceutical industry

Recently, the prevalence of allergic conjunctivitis has increased due to factors like rapid urbanization and an increasing number of allergens.

Key Points: 
  • Recently, the prevalence of allergic conjunctivitis has increased due to factors like rapid urbanization and an increasing number of allergens.
  • United States dominates Global Allergic Conjunctivitis Market, Patients Population & Treated Patients Population
    As per our analysis, the United States stands out as the largest market for allergic conjunctivitis treatments due to the high prevalence of allergic conjunctivitis.
  • Our report covers numerous Disease Type variants like Seasonal Allergic Conjunctivitis (SAC) & Perennial Allergic Conjunctivitis (PAC), Vernal Keratoconjunctivitis (VKC), Atopic Keratoconjunctivitis (AKC), and Giant Papillary Conjunctivitis (GPC).
  • The increase in awareness of allergic conjunctivitis associated with medical treatment & upcoming therapies is enhancing the market expansion.

Seth Rogen and Lauren Miller Rogen to Accept Award at Commitment to Cures on April 6 in Support of Brain Disease Research

Retrieved on: 
Wednesday, March 9, 2022
217th Brigade (United Kingdom), Humour, MS, Instagram, Commitment, AM, Sheila Essey Award, Niemann–Pick disease, type C, Brain on Fire, Foundation, Disorder, Stroke, Ambassador Award, Disease, Potamkin Prize, LinkedIn, Center for Public Leadership, ABF, Doctor of Philosophy, Patient, Autoimmune disease, Vascular dementia, MAS, Neurological disorder, Awareness, MBBS, Life, Autoimmune encephalitis, Research, Leadership, Hospital, Dementia, DM, Ambassador, FRCP, Seth Rogen's Hilarity for Charity, DSC, Association, FAAN, The New York Times, Work, Multiple sclerosis, Twitter, American Brain Tumor Association, ALS, FWSO, Humanism, Education, MBA, Master of Science, FICP, DNB, Diagnosis, Medical device, Medical imaging, Pharmaceutical industry, Medicine, Alzheimer's disease, Pick, Facebook, Neurology, MD, Brain

The goal of the gala is to raise awareness and funds for brain disease research, because without research, there can be no cures.

Key Points: 
  • The goal of the gala is to raise awareness and funds for brain disease research, because without research, there can be no cures.
  • The American Brain Foundation takes a whole-brain approach to research based on the understanding that when we cure one brain disease, we will cure many.
  • Commitment to Cures provides an occasion to honor those who are making an impact in the field of brain disease research.
  • About the American Brain Foundation:
    The American Brain Foundation was founded to bring researchers and donors together in the fight against brain disease.

Cyclo Therapeutics Selected to Present Overview of Pivotal Phase 3 Study for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2022

Retrieved on: 
Tuesday, February 8, 2022
Research, Genetics, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Niemann–Pick disease, U.S. Securities and Exchange Commission, Abstract (summary), Protocol, GSC, SOC, CA, Safety, Risk, Niemann–Pick disease, type C, Walking, Disease, Expanded access, Standard of care, Week, Trial of the century, Doctor of Philosophy, Research, Company, Therapy, Poster, FDA, NPC, Security (finance), Hope, CYTH, MD, Frontier Organic Research Farm Botanical Garden, NPC1, Swallow, Clinical trial, Form 10-K, Patient, EMA, Priority review, Cyclo, Fine motor skill, Glycogen storage disease, Science, Adult, Population, Internet, WORLD, Nasdaq, Cognition, PIP, Pharmaceutical industry, Speech, EU

We are dedicated to progressing this trial and look forward to the new insights it will provide, commented Dr. Lise Lund Kjems.

Key Points: 
  • We are dedicated to progressing this trial and look forward to the new insights it will provide, commented Dr. Lise Lund Kjems.
  • The Phase 3 study intends to enroll at least 93 pediatric (age 3 years and older) and adult patients with NPC1 in at least 23 study centers in 9 countries.
  • Eligible patients will be randomized 2:1 to receive either Trappsol Cyclo or a placebo.
  • For more information about the Companys TransportNPC pivotal Phase 3 study, visit www.ClinicalTrials.gov and reference identifier NCT04860960 .